Physician profile
Rickell Gordon
NPI 1093132052
$4,836.67
in general payments reported to CMS, 2019-2025
16 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.41 · 2022: $22.80 · 2023: $1,361 · 2024: $1,140 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,792.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,072.60 | 2024-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,045.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $804.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $469.64 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $349.41 | 2023-2025 | |
| Exact Sciences Corporation | $273.61 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $239.00 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $168.50 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $153.82 | 2023-2025 | |
| Glaxosmithkline, LLC. | $99.94 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $35.66 | 2023 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $33.80 | 2023 | Uzedy, Austedo Xr |
| Phathom Pharmaceuticals, INC. | $30.80 | 2023 | Voquezna |
| Neurocrine Biosciences, INC. | $22.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.41 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rickell Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.